+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A Case of Long-Term Survival of Metastatic and Recurrent Duodenal Gastrointestinal Stromal Tumor Treated with Multimodality Managements



A Case of Long-Term Survival of Metastatic and Recurrent Duodenal Gastrointestinal Stromal Tumor Treated with Multimodality Managements



Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(3): 527-529



We hereby report a case of long-term survival of metastatic and recurrent duodenal gastrointestinal stromal tumor(GIST) treated with multimodality managements. A 59-year-old man was diagnosed with duodenal GIST and underwent surgical resection of a primary lesion of the duodenum. Since the pathological findings on mitotic rate indicated its high risk of recurrence, the systemic treatment by imatinib mesylate was given shortly after the surgery. Six months later, metastatic lesions being considered to be imatinib-resistant were observed in the remnant liver. Since there were no other drugs available for GISTs in clinic at that time, surgery of central bisegmentectomy with partial resection of the liver was performed to eliminate all metastatic lesions. However, recurrences had been repeatedly diagnosed afterward. In response to them, four more surgery for recurrent liver or peritoneal tumors, two transcatheter arterial chemoembolizations(TACE)and one radiofrequency ablation(RFA)were performed on the basis of its resectability. Sunitinib malate had been given since it was approved for imatinib-resistant GISTs in clinic. Eventually, as long as 99 months had passed since we observed the first evidence of the resistance to imatinib mesylate when he died from the GIST.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 043460554

Download citation: RISBibTeXText

PMID: 29650927


Related references

Long-term survival in a case of recurrent gastrointestinal stromal tumor treated with intermittent or low-dose imatinib. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(3): 379-382, 2014

A long-term survival case with multiple liver metastases from duodenal gastrointestinal stromal tumor that was drastically reduced by the treatment with imatinib. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(11): 1739-1741, 2005

Long-term survival of a case with multiple liver metastases from duodenal gastrointestinal stromal tumor drastically reduced by the treatment with imatinib and hepatectomy. World Journal of Gastroenterology 12(17): 2793-2797, 2006

A Case of Rectal Gastrointestinal Stromal Tumor(GIST)with Long-Term Survival Treated with Multidisciplinary Therapy. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(13): 2288-2290, 2018

A case of recurrent duodenal gastrointestinal stromal tumor resistant to imatinib and sunitinib, successfully treated with regorafenib. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(12): 1545-1547, 2014

Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort. Acta Oncologica 56(10): 1317-1323, 2017

A case of recurrent gastrointestinal stromal tumor progressing after interruption of long-term imatinib therapy. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(12): 2478-2480, 2014

Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience. Cancer Medicine 8(3): 1034-1043, 2019

Long-term progression-free survival after reduction surgery and postoperative low-dose imatinib administration for multiple liver metastases of duodenal gastrointestinal stromal tumor. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(6): 979-982, 2012

Duodenal gastrointestinal stromal tumor: clinicopathological characteristics, surgical outcomes, long term survival and predictors for adverse outcomes. American Journal of Surgery 206(3): 360-367, 2013

Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: report of a case. Surgery Today 38(1): 65-67, 2008

Long-Term Survival of a Patient with Recurrent Duodenal GIST Treated with Various Molecular Targeted Drugs and TAE - A Case Report. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 43(12): 2362-2364, 2016

Long-term survival after excision of a giant esophageal gastrointestinal stromal tumor with imatinib mesylate resistance: report of a case. Surgery Today 44(9): 1764-1767, 2014

A case of gastrointestinal stromal tumor (GIST) successfully treated with resection after a long-term control medication by molecular targeted drugs. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(12): 2378-2380, 2011

Six years survival on imatinib with no disease progression after diagnosis of metastatic duodenal gastrointestinal stromal tumour: a case report. Journal of Medical Case Reports 2: 110, 2008